Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Japan's First IP Fund Starts Operation
November 1, 2010
- Diagnostic Imaging Is Japan's Advantage: Ms Sawada of Shionogi
November 1, 2010
- Catalent Embarks on Master Cell Bank Development Business in Japan
November 1, 2010
- Vidaza Recommended for Approval
November 1, 2010
- “Medical Innovation Center Scheme”Proposed by Dr Kayama
November 1, 2010
- Takeda to Accelerate Business Development in China
November 1, 2010
- US FDA Issues Warning to Kyowa Hakko Bio
November 1, 2010
- New Tools Expected to Be Useful for Drug Development: Dr Uyama of PMDA
November 1, 2010
- Prime Minister Kan Calls on Industry to Invest More in Japan
November 1, 2010
- Healthcare, Nursing Care Drive Japan's Economic Growth: Health Minister Hosokawa
November 1, 2010
- Pharma Industry Contributes to Int'l Balance of Technical Fee Payments
November 1, 2010
- JPMA Issues Warning to MSD on Violation of Promotion Code
November 1, 2010
- Global Pharma Market to Reach US$880 Bil. in 2011: IMS Health
November 1, 2010
- Asahi Kasei Pharma Applies for Teriparatide in Japan
November 1, 2010
- Shionogi Begins PIII for Next-Generation Anti-HIV Drug
November 1, 2010
- NV1FGF Fails to Meet PIII Primary Endpoint
November 1, 2010
- Korosho Warns against Allergic Reactions to Hydrolyzed Wheat Powder
November 1, 2010
- Takeda Applies for Successor of Candesartan
November 1, 2010
- Takara Bio Begins Leukemia Gene Therapy in 1st Subject
November 1, 2010
- Iressa Fails to Extend OS in 1st Line Treatment for NSCLC
November 1, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…